You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – The Canadian Cancer Trials Group on Monday said that it has opened a new protocol involving Treadwell Therapeutics' investigational PLK4 inhibitor, CFI-400945, within an ongoing Phase II umbrella trial.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.